Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing

Prostate cancer is the second most frequent malignancy in men worldwide. Despite the improvement in survival achieved by increasingly early diagnosis and advances in treatment, it is still associated with high mortality. Because of its molecular heterogeneity, there is a need to identify genetic alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogueira Costa, Inês, Reis, Joana, Meireles, Sara, Ribeiro, Maria João, Barbosa, Miguel, Augusto, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239024/
https://www.ncbi.nlm.nih.gov/pubmed/35774732
http://dx.doi.org/10.12890/2022_003331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239024/
https://www.ncbi.nlm.nih.gov/pubmed/35774732
http://dx.doi.org/10.12890/2022_003331

Ejemplares similares